High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice

Oncologist

Volumn 13, Issue 12, 2008, Pages 1270-1275

  Santini, Daniele ^a   Loupakis, Fotios ^b,c   Vincenzi, Bruno ^a   Floriani, Irene ^d   Stasi, Irene ^b   Canestrari, Emanuele ^e   Rulli, Eliana ^d   Maltese, Paolo Enrico ^b   Andreoni, Francesca ^e   Masi, Gianluca ^b   Graziano, Francesco ^f   Baldi, Giacomo Giulio ^b   Salvatore, Lisa ^b   Russo, Antonio ^g   Perrone, Giuseppe ^a   Tommasino, Maria Rosa ^h   Magnani, Mauro ^e   Falcone, Alfredo ^b,c   Tonini, Giuseppe ^a   Ruzzo, Annamaria ^e  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e UNIVERSITY OF URBINO   (Italy)

^f SAN SALVATORE HOSPITAL   (Italy)

^g Sezione di Oncologia Medica   (Italy)

^h UNIVERSITY OF PALERMO   (Italy)

Author keywords

Colorectal cancer; Concordance; Kras mutations; Metastatic sites; Primary tumors

Indexed keywords

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CLINICAL PRACTICE; CODON; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; KRAS GENE; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TISSUE SECTION; TUMOR GENE;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 58749102224     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0181     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy. Cancer 2002;94:1593-1611.
3. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
4. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-1810.
5. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study. J Natl Cancer Inst 1998;90:675-684.
6. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 2001;85:692-696.
7. Bos JL. ras oncogenes in human cancer: A review. Cancer Res 1989;49:4682-4689.
8. Lièvre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-3995.
9. Lièvre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-379.
10. Di Fiore F, Blanchard F, Charbonnier F et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-1169.
11. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643-2648.
12. De Roock W, Piessevaux H, De Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-515.
13. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-3237.
14. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
15. Scartozzi M, Bearzi I, Berardi R et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004;22:4772-4778.
16. Cappuzzo F, Finocchiaro G, Rossi E et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2008;19:717-723.
17. Scartozzi M, Bearzi I, Berardi R et al. Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: Optimising EGFR-targeted treatment options. Br J Cancer 2007;97:92-97.
18. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532.
19. Oliveira C, Velho S, Moutinho C et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 2007;26:158-163.
20. Frattini M, Balestra D, Suardi S et al. Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res 2004;10:4015-4021.
21. A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med 2001;20:859-866.
22. Molinari F, Martin V, Bordoni A et al. Analysis of epidermal growth factor receptor (EGFR) gene status and protein expression, and K-ras gene mutations in metastatic colorectal cancer patients: Comparison between primary tumor and related metastatic sites. Ann Oncol 2008;19(suppl 1):i10-i25.
23. Zhu D, Keohavong P, Finkelstein SD et al. K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients. Cancer Res 1997;57:2485-2492.
24. Van Cutsem E, Nowacki M, Lang I et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 2007;25(18 suppl):4000.
25. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.